MedTrace Logo

Assess the Safety and Tolerability of SNS851 in Healthy Participants

NCT07417124 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-03-23

No results posted yet for this study

Summary

This is a Phase I, randomized, double-blind study designed to evaluate the safety, tolerability and pharmacokinetics of subcutaneous administration of SNS851 in healthy participants.

Conditions

  • Metabolic Disease

Interventions

DRUG

SNS851

SNS851 is a potent siRNA treatment targeting metabolic diseases.

OTHER

Placebo

Normal saline

Sponsors & Collaborators

  • Oneness Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07417124 on ClinicalTrials.gov